NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES
Oslo, Norway, 5 June 2015
Vistin Pharma ASA (OSE: VISTIN), reference is made to the previous stock exchange announcements regarding the sale of Weifa ASA's B2B business and tablet production to Vistin Pharma AS, and the offering and listing on Oslo Axess of 17,054,935 new shares in Vistin Pharma ASA (the "Company") at a subscription price of NOK 10.00 per share.
The subscription period in the Rights Offering and Employee Offering expired on 4 June 2015. Both tranches were significantly oversubscribed, resulting in gross proceeds of NOK 170,549,350 through the issuance of 15,554,935 shares in the Rights Offering and 1,500,000 shares in the Employee Offering.
Notifications of allocated new shares and the corresponding amount to be paid by each subscriber will be sent to the subscribers today, 5 June 2015. Subscribers having access to investor services through their VPS account will be able to check the number of new shares allocated from 14:00 CET today. Subscribers may also contact Carnegie at +47 22 00 93 64, from 14:00 CET today, to obtain information about the number of new shares allotted. Payment for the allocated new shares falls due on 9 June 2015.
Subject to payment being received when due, the new shares are expected to be delivered to the respective subscribers' VPS account on or about 10 June 2015. The new shares may not be transferred or traded until they are fully paid by the individual subscriber.
The new shares are expected to commence trading on Oslo Axess on or about 10 June 2015.
Following the registration of the new share capital in the Norwegian Register of Business Enterprises, and the simultaneous share capital reduction of the 1,000,000 existing shares in the Company owned by Weifa ASA, the Company will have 17,054,935 shares outstanding, each with a par value of NOK 1.
For further information, please contact:
Kjell-Erik Nordby
CEO
+47 913 64 280
Kjell-erik.nordby@vistin.com
Gunnar Manum
CFO
+47 951 79 190
gunnar.manum@vistin.com
Important information:
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia).
This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions.
The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Carnegie is acting for the Company and no one else in connection with the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Offering and/or any other matter referred to in this release.
***